Intravenous injection of apelin-13 improves sensory-motor balance deficits caused by cerebral ischemic reperfusion injury in male wistar rats via restoration of nitric oxide.
Apelin-13
Cerebral ischemia/reperfusion injury
Nitric oxide
Sensory-motor balance defects
Journal
Journal of chemical neuroanatomy
ISSN: 1873-6300
Titre abrégé: J Chem Neuroanat
Pays: Netherlands
ID NLM: 8902615
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
29
08
2020
revised:
10
11
2020
accepted:
10
11
2020
pubmed:
16
11
2020
medline:
1
10
2021
entrez:
15
11
2020
Statut:
ppublish
Résumé
It has been reported that apelin-13 possesses neuroprotective effects against cerebral ischemia/reperfusion injury (IRI). Disabilities in sense, movement and balance are the major stroke complications which, result in a high rate of mortality. Here, effects of intravenous (IV) injection of apelin-13 on the severity of neural death, infarct volume, neurological defects and its association with nitric oxide (NO) were investigated. A rat model of cerebral IRI was created by middle cerebral artery occlusion (MCAO) for 60 min and restoration of blood flow for 23 h. Animals were randomly assigned into six groups: sham, ischemia (MCAO), vehicle (MCAO + PBS) and three treatment groups (MCAO + apelin-13 in 10, 20, 40 μg/kg doses, IV). All injections were carried out via tail vein injection 5 min before reperfusion. Neural loss and infarct volume were evaluated by Nissl and 2,3,5-triphenyltetrazolium chloride (TTC) staining, respectively. Neurological defects were scored by standard modified criteria. Serum NO was measured by colorimetric method. Apelin-13 in doses of 20 and 40 μg/kg significantly reduced neural death, infarct volume and disturbance of sensory-motor balance compared to control and vehicle groups (p < 0.05). Serum NO levels reduced in MCAO groups compared to sham. Apelin-13 restored serum NO levels at 20 μg/kg dose (p < 0.05). Our data showed beneficial effect of IV injection of apelin-13 on sensory-motor balance defects by reducing neural death and restoration of serum NO levels. The present study shows the validity of apelin-13 in treatment of ischemic stroke in different administration methods.
Identifiants
pubmed: 33189869
pii: S0891-0618(20)30155-1
doi: 10.1016/j.jchemneu.2020.101886
pii:
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Neuroprotective Agents
0
apelin-13 peptide
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101886Informations de copyright
Copyright © 2020. Published by Elsevier B.V.